Exscientia plc (EXAI)

NASDAQ: EXAI · IEX Real-Time Price · USD
18.80
0.79 (4.39%)
At close: Jan 14, 2022 4:00 PM
18.85
0.05 (0.27%)
After-hours:Jan 14, 2022 4:00 PM EST
Market Cap2.26B
Revenue (ttm)14.49M
Net Income (ttm)-54.08M
Shares Out120.39M
EPS (ttm)-0.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume30,981
Open17.64
Previous Close18.01
Day's Range17.64 - 18.85
52-Week Range17.02 - 30.38
Betan/a
AnalystsBuy
Price Target30.00 (+59.6%)
Earnings DateNov 17, 2021

About EXAI

Exscientia is an artificial intelligence-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Our goal is to change the pharmaceutical industry’s underlying pharmacoeconomic model, what we call "Shifting the Curve", by improving the probability of success, time and cost involved with creating new medicines. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates. We have built a comple...

IndustryBiotechnology
IPO DateOct 1, 2021
CEOAndrew L. Hopkins, DPhil
Employees208
Stock ExchangeNASDAQ
Ticker SymbolEXAI
Full Company Profile

Financial Performance

Financial numbers in millions GBPFinancial Statements

Analyst Forecast

According to 4 analysts, the average rating for Exscientia stock is "Buy." The 12-month stock price forecast is 30.00, which is an increase of 59.57% from the latest price.

Price Target
$30.00
(59.57% upside)
Analyst Consensus: Buy

News

Shares of Sanofi, Exscientia Rise on News of Collaboration

Shares of Exscientia PLC ( EXAI , Financial) got a nice boost last week when the U.K.-based biotech announced it signed a research collaboration and license agreement with large drugmaker Sanofi SA ( SN...

Other symbols:SNY
5 days ago - GuruFocus

Sanofi, Exscientia sign development deal worth up to $5.2 billion

Shares of Exscientia EXAI, -2.05% jumped 14.3% in premarket trading on Friday after it announced a deal with Sanofi SNY, -0.24% to develop up to 15 new oncology and immunology drug candidates using Exsc...

Other symbols:SNY
1 week ago - Market Watch

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineere...

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

Other symbols:SNY
1 week ago - GlobeNewsWire

Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia's founder and CEO, Ben Taylor, CFO & Chief Strategy Officer, and Garry Pairaudeau, Chi...

1 month ago - Business Wire

Exscientia Business Update for Third Quarter 2021

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI): Recent advancements in the Company's pipeline, collaborations and operations as well as financial results for the third quarter ended Septemb...

1 month ago - Business Wire

Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective ...

2 months ago - Business Wire

Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platfo...

VIENNA & OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, today anno...

3 months ago - Business Wire

Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Publ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effect...

3 months ago - Business Wire